Cambridge, United States
Synlogic, founded in 2014 and headquartered in the United States, is a clinical-stage biotechnology company with a mission aptly captured by its slogan, “Designed for Life.” The company is advancing a robust pipeline of novel, oral, non-systemically absorbed biotherapeutics, strategically targeting serious diseases lacking effective treatments.
At the forefront of Synlogic’s late-stage pipeline is labafenogene marselecobac (SYNB1934), currently in a pivotal Phase 3 trial for treating phenylketonuria (PKU). The innovative Synthetic Biotic platform underpins their approach, employing precision genetic engineering to develop GI-restricted oral medicines purpose-built to alter disease-specific metabolites—a strategy ideal for conditions like PKU and homocystinuria (HCU).
Synlogic’s collaborative efforts further strengthen its proposition, including partnerships with Roche on inflammatory bowel disease and Ginkgo Bioworks in synthetic biology. Having raised $21.00M in a post-IPO equity investment on 29 September 2023, Synlogic is well-positioned in the biotechnology and health sectors.
